Angiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1/PD-L1 immune checkpoint blockers.

Affiliation auteurs!!!! Error affiliation !!!!
TitreAngiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1/PD-L1 immune checkpoint blockers.
Type de publicationJournal Article
Year of Publication2019
AuteursMedjebar S, Richard C, Fumet J-D, Malo J, Elkrief A, Blais N, Tehfe M, Florescu M, Boidot R, Truntzer C, Routy B, Ghiringhelli F
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2019.37.15_suppl.e20512